Affimed to Present at Jefferies Virtual Cell Therapy Summit

Rhea-AI Summary

Heidelberg, Germany, September 29, 2020 – Affimed N.V. (Nasdaq: AFMD) announced its presentation at the Jefferies Virtual Cell Therapy Conference on October 6 at 8:00 a.m. Eastern Time. The event's live webcast will be accessible via the “Investors” section on Affimed’s website and will remain available for 30 days post-event. Affimed focuses on innovative immuno-oncology treatments, leveraging its ROCK® platform for tailored therapies aimed at hematologic and solid tumors. The company is currently advancing studies on AFM13 and AFM24.

Heidelberg, Germany, September 29, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the company’s management will present at the Jefferies Virtual Cell Therapy Conference on Tuesday, October 6 at 8:00 a.m. Eastern Time.

A live webcast of the presentation can be accessed under the “Investors” section of Affimed’s website at https://www.affimed.com/investors/webcasts_cp/ and will be available for 30 days following the event.

About Affimed N.V.

Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer. Affimed’s fit-for-purpose ROCK® platform allows innate cell engagers to be designed for specific patient populations. The company is developing single and combination therapies to treat hematologic and solid tumors. The company is currently enrolling patients into a registration-directed study of AFM13 for CD30+ relapsed/refractory peripheral T cell lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. For more information, please visit www.affimed.com.

Affimed Investor Contact

Alexander Fudukidis
Head of Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: (917) 436-8102

FAQ

When is Affimed's presentation at the Jefferies Virtual Cell Therapy Conference?

Affimed's presentation is scheduled for October 6, 2020, at 8:00 a.m. Eastern Time.

How can I watch Affimed's presentation?

You can watch the presentation live via the 'Investors' section on Affimed's website.

What is Affimed's focus in cancer treatment?

Affimed specializes in immuno-oncology, creating therapies using their ROCK® platform for targeting specific patient populations.

What studies is Affimed currently conducting?

Affimed is enrolling patients in studies for AFM13 targeting CD30+ relapsed/refractory peripheral T cell lymphoma and AFM24 for advanced EGFR-expressing solid tumors.

How long will the webcast of Affimed's conference be available?

The webcast will be available for 30 days following the event.